PATENT CLAIM ANALYSIS

Application Number: 15743756
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-09
Patent Classification: ["530", "387300"]

Abstract:
The present disclosure relates to antibody molecules comprising a binding domain specific to CD22, said binding domain comprising SEQ ID NO: 1, 2, 3, 4, 5 and 6 or 7. The disclosure also extends to pharmaceutical compositions comprising said antibody molecules and use of the antibody molecules/compositions in treatment.

Claim (Index 41):
The antibody molecule according to  claim 3 , comprising a VH independently selected from SEQ ID NO: 107, 108, 109, 110, 116, 117, 118, 119, 120, 121, 127, 128, 129, 130, 136, 137, 138, 139, 145, 146, 147, 148, 154, 155, 156 and 157.

Metadata:
- Claim Count in Document: 2.0
- Percentile: 86.0
- Lexical Diversity: 1.46154
- Patent Class: 530.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['15743764', '15326501', '15627161', '15430998', '13107439']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7539024620590309
- 35 USC 102 Novelty (BERT): 0.6182187106418838
- Combined Prediction Score: 0.7403340869173162
- Mean Citation Score: 451.072982
- Max Citation Score: 608.11847
- Similarity Product: 458.18050372686736

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test